|
|||||
|
|
| 帕博利珠单抗联合化疗在PD-L1阴性晚期非小细胞肺癌中的汇总分析 | |
| 引用本文： | 黄诚. 帕博利珠单抗联合化疗在PD-L1阴性晚期非小细胞肺癌中的汇总分析[J]. 循证医学, 2021, 21(4): 214-219. DOI: 10.12019/j.issn.1671-5144.2021.04.005 |
| 作者姓名： | 黄诚 |
| 作者单位： | 福建省肿瘤医院胸部肿瘤科, 福州 350011 |
| 摘 要： | |
| 关 键 词： | 抗肿瘤药物 联合药物治疗 非小细胞肺癌 帕博利珠单抗 程序性细胞死亡配体1（人源CD274蛋白） |
Pooled Analysis of Pembrolizumab Plus Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients Without Tumor PD-L1 Expression |
|
| HUANG Cheng. Pooled Analysis of Pembrolizumab Plus Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients Without Tumor PD-L1 Expression[J]. The Journal of Evidence-Based Medicine, 2021, 21(4): 214-219. DOI: 10.12019/j.issn.1671-5144.2021.04.005 | |
| Authors: | HUANG Cheng |
| Affiliation: | Reviewer's address: Department of Thoracic Oncology, Fujian Provincial Cancer Hospital, Fuzhou 350011, ChinaAbastract |
| Abstract: | |
| Keywords: | antineoplastic agents combined drug therapy non-small cell lung cancer pembrolizumab programmed cell death ligand 1 protein （human CD274 protein） |
| 点击此处可从《循证医学》浏览原始摘要信息 | |
| 点击此处可从《循证医学》下载免费的PDF全文 | |